Before the economy and struggling stocks completely recover, investors may want to consider buying shares of Merck (NYSE: MRK), JPMorgan Chase (NYSE: JPM), and American Airlines (NASDAQ: AAL), which could be performing a whole lot better a year from now. Healthcare company Merck has had a tough year, mostly because hospitals are deferring procedures and people aren't making their usual trips to the doctor's office. In its earnings release, Merck reported that the pandemic has negatively affected its pharmaceutical revenue to the tune of about $475 million during the past quarter and $2.1 billion since the start of the year.
Let's see if Merck & Co (MRK) stock is a good choice for value-oriented investors right now from multiple angles.
The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.